Use of pharmacokinetic/pharmacodynamic biomarkers to support rational cancer drug development

Debashis Sarker, Simon Pacey, Paul Workman

Research output: Contribution to journalArticlepeer-review


The process of drug development in oncology has struggled to alter at a pace in keeping with the rapid discovery and testing of agents that act on a wide variety of molecular targets. The rational development of such agents requires an understanding of drug effect(s) on their purported target. It is likely that testing these drugs in a framework designed to examine cytotoxic agents will fail to establish their full potential. We discuss how data gained from biomarker investigation might impact on drug development and provide examples that highlight the development, validation and use of pharmacokinetic, and especially pharmacodynamic biomarkers as drug development moves from the laboratory into clinical testing. The challenges of performing assays to satisfy regulatory requirements have been the subject of much debate. We recommend the implementation of appropriate, fit-for-purpose biomarkers in clinical trials of all new cancer drugs.
Original languageEnglish
Pages (from-to)399-417
Number of pages19
JournalBiomarkers in Medicine
Issue number3
Publication statusPublished - Oct 2007


Dive into the research topics of 'Use of pharmacokinetic/pharmacodynamic biomarkers to support rational cancer drug development'. Together they form a unique fingerprint.

Cite this